StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Next report date, year-over-year trend, and recent quarter history.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
Factor scoring needs Finnhub-supplied fundamentals — Finnhub returned no fundamental metrics for this ticker. Common for ETFs, foreign filers without US listing depth, recent IPOs, and thinly-traded OTC names.
6-factor scoring with sector-relative rank. Updated daily.
Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-11 | $4.76 | $4.70 | -1.26% | 0.0M |
| 05-12 | $4.63 | $4.78 | +3.24% | 0.0M |
| 05-13 | $4.67 | $4.83 | +3.43% | 0.0M |
| 05-14 | $4.93 | $5.00 | +1.42% | 0.0M |
| 05-15 | $4.81 | $4.78 | -0.62% | 0.0M |
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $26.00K | $7.70M | $5.20M | $3.03M |
Operating Income | $-7.60M | $-36.11M | $-29.03M | $-21.32M |
Net Income | $-7.24M | $-33.38M | $-26.75M | $-19.60M |
EPS (Diluted) | $-4.31 | $-17.85 | $-13.94 | $-10.22 |
Total Assets | $48.03M | $56.75M | $65.05M | $75.50M |
Total Liabilities | $28.20M | $30.24M | $32.95M | $36.66M |
Cash & Equivalents | $11.61M | $11.70M | $17.75M | $9.60M |
Free Cash Flow OCF − CapEx | Not available | $-39.92M | $-32.77M | Not available |
Shares Outstanding | 1.92M | 1.92M | 1.92M | 1.92M |
No sell-side coverage available for BOLT.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
Fundamentals not available for BOLT.
No fundamental metrics available yet for this ticker — common for ETFs, foreign issuers without US listing depth, very recent IPOs, or thinly-traded OTC names. The Financials tab pulls from SEC EDGAR directly and may still have data.
Bolt Biotherapeutics Inc is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. The company is focused on the clinical development of BDC-4182, its claudin 18.2 ISAC. Its other pipeline programs include CEA ISAC program a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5, or CEA; PD-L1 ISAC utilizes a novel human anti-PD-L1 antibody conjugated to a next-generation TLR7/8 agonist payload via a non-cleavable linker; and BDC-3042, its dectin-2 agonist antibody program, developed to repolarize critical cells in the tumor microenvironment known as tumor associated macrophages. It operates in single segment.